Results 151 to 160 of about 55,945 (286)

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen   +2 more
wiley   +1 more source

Targeting the noradrenergic‐metabolic axis: A new strategy for sugar‐induced depression subtypes

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Lifestyle is closely related to major depressive disorder (MDD). Given the growing focus on the impact of diet on mental health, this study examined how dietary habits affect the pathophysiology of MDD. Experimental Approach Health check‐up data were analysed. Mice received sucrose under chronic unpredictable mild stress
Takatoshi Sakata   +13 more
wiley   +1 more source

Histamine Receptors Regulate the Activity, Surface Expression, and Phosphorylation of Serotonin Transporters. [PDF]

open access: yesACS Chem Neurosci, 2020
Annamalai B   +5 more
europepmc   +1 more source

Protectin D1 and maresin 1 attenuate airway hyperreactivity induced by IL‐13 in human isolated small bronchi

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Interleukin (IL)‐13 is implicated in airway hyperreactivity (AHR), a key feature of asthma. We explored the potential anti‐AHR activity of selected specialised pro‐resolving mediators (SPMs) in IL‐13‐induced AHR models, using human bronchial smooth muscle cells (BSMCs) and human isolated bronchi.
Willem Abma   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy